This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
ITPP
Myo-Inositol Trispyrophosphate | OXY111A — investigational allosteric hemoglobin effector
Aliases (4)
Overview
What is ITPP?
ITPP (myo-inositol trispyrophosphate; clinical development name OXY111A) is a small synthetic polyanion that allosterically modifies hemoglobin to release more oxygen at tissue PO2. It is NOT a peptide and NOT a SARM. It was developed in the Lehn group (Strasbourg) and advanced by NormOxys/OXY111A program toward hepatocellular carcinoma and sickle cell indications. It carries orphan-drug status only and has not progressed to FDA approval. WADA-prohibited under M1.2.
Key Benefits
Mechanistically clean enhancement of tissue oxygen delivery — every red cell offloads more O2 per pass without changing hematocrit. Strong rodent endurance + cardiac stress tolerance signal. Oncology rationale: relieves tumor hypoxia and improves chemotherapy efficacy. None of these benefits has been validated in humans outside small oncology trials.
Mechanism of Action
ITPP binds the central cavity of the hemoglobin tetramer — the same site where the natural allosteric effector 2,3-BPG (2,3-bisphosphoglycerate) binds — but with substantially higher affinity. Binding stabilizes the T (tense, deoxy) state of hemoglobin, shifting the oxyhemoglobin dissociation curve rightward. This means at any given tissue PO2, more oxygen is released from hemoglobin to the tissue. P50 (the PO2 at which hemoglobin is 50% saturated) increases.
Pharmacokinetics
Research Indications
What hemoglobin actually does — the part the textbooks gloss
Hemoglobin (Hb) is a tetramer (two α and two β chains, each with a heme/iron center). Its job is to bind O2 in the lung (high PO2) and re…
Where ITPP fits
ITPP is a synthetic polyanion designed by the Jean-Marie Lehn group (Université de Strasbourg, Nobel laureate in chemistry 1987) in colla…
Net physiological consequence
- At the lung (high PO2 ~100 mmHg): Hb still saturates near 100% — the right-shift mostly affects the unloading end of the curve. - At th…
vs other oxygen-economy mechanisms
- EPO / erythropoiesis-stimulating agents. Increase RBC mass — more carriers. Effect takes weeks (RBC maturation). Raises hematocrit, vis…
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Ensures RBC mass and Hb concentration are adequate to actually carry the oxygen the modified Hb will offload more efficiently. Iron-deficient state nullifies…
ITPP works on the unloading side of the curve; training increases capillary density, mitochondrial density, and tissue O2 utilization. The two layers are mec…
Layered O2-economy modifiers, layered WADA violations, no clinical data.
Conflicting hypoxia signals + WADA banning.
Stacked O2-economy modifiers + multiple WADA M1 violations.
Too many novel signals at once + cumulative WADA exposure + attribution becomes impossible.
Additive renal load.
Quality Indicators
No Pharmacopoeial Standard
ITPP is not in USP, EP, or BP. No reference standard exists for non-trial use. Vendor 'COA' documents in the gray market are unverifiable.
Polyphosphate Stability
Pyrophosphate bonds are hydrolyzable; improper handling, moisture exposure, or acidic conditions can degrade ITPP to inositol phosphate fragments with no oxygen-modifying activity.
Gray-Market Sourcing Reliability Extremely Low
ITPP appeared briefly on research-chem markets around 2014-2018 and has been intermittent since. Vendor identification of the molecule by mass spec or HPLC is rarely independently verified. High risk of misidentification, contamination, or sub-active material.
WADA M1.2 Prohibited
Listed under WADA Prohibited List Section M1.2 'Artificial enhancement of the uptake, transport, or delivery of oxygen.' Banned in and out of competition. Detection methodology has been published; ITPP residues in urine and dried blood spots are detectable.
No FDA Approval; OXY111A Stalled
Clinical development as OXY111A (NormOxys / OXY111A program) had limited progression; no Phase 3 data, no approved indication. Orphan-drug designation only.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 10
Side Effects
- 1Transient hypotension — IV polyanions can produce acute BP drops; reported in some anecdotal accounts.
- 2Mild headache — possibly cerebral perfusion / acid-base related.
- 3Nausea — IV-related; usually self-limiting.
- 4Injection-site irritation for IM/IP attempts.
- 5Renal phosphate handling. Polyphosphate dosing at gram-per-kg cumulative levels imposes significant renal phosphate clearance load. Acute and chronic kidney injury risk is uncharacterized in humans. This alone is enough to require eGFR + serum phosphate + urinalysis monitoring for any cycle.
- 6Excessive right-shift. A sufficiently large P50 shift could theoretically impair pulmonary loading at high altitude or in pulmonary disease — Hb at low O2 affinity loads less efficiently in the lung. The therapeutic window for oxygen-economy modification is finite.
- 7Effect on bone marrow / erythropoiesis. Tissue-level hyperoxia from enhanced O2 delivery would, in principle, reduce endogenous EPO production via the renal O2-sensing pathway (the inverse of the HIF-PHI mechanism). Chronic suppression of erythropoiesis is a theoretical concern not characterized in humans.
- 8Peripheral chemoreceptor desensitization. Carotid body O2 sensing influences ventilatory drive, sympathetic tone, and CV regulation. Sustained tissue hyperoxia could remodel chemoreceptor sensitivity in unpredictable ways.
- 9Coagulation interaction. Inositol hexaphosphate (phytate) and related polyanions can interact with coagulation cascade components in vitro. Clinical relevance for ITPP at therapeutic doses is uncharacterized.
- 10Hemoglobinopathies. Effect in patients with abnormal hemoglobins (HbS, HbC, thalassemias, methemoglobinemia) is variable and complex. In SCD, the effect is theoretically beneficial; in some other contexts it could be deleterious.
When to Stop
- Acute hypotensive collapse with rapid IV bolus. Polyanion bolus + acute BP changes.
- Acute kidney injury from phosphate load in patients with subclinical renal impairment.
- Ventilatory dysregulation with sustained tissue hyperoxia (theoretical).
- Cardiac arrhythmia secondary to electrolyte shifts from large phosphate loads (theoretical).
- Pre-cycle: CMP, eGFR, serum phosphate, calcium, urinalysis, CBC, BP, baseline ECG, baseline cardio benchmark.
- During cycle: BP daily; serum phosphate + creatinine weekly; symptom log (headache, exertional dyspnea, fatigue) daily.
- Post-cycle: Repeat full panel at 2 weeks and 8 weeks post-cessation. Any abnormality → permanent discontinuation.
- Any chronic kidney disease, eGFR <90, or proteinuria
- Pulmonary hypertension or right-heart dysfunction (paradoxically — despite preclinical PH benefit, off-label use is not validated)
- Active malignancy outside an approved oncology trial protocol
- Hemoglobinopathy not under hematologist supervision
- Pregnancy / lactation (zero data)
- Pediatric use (zero data)
- Tested athletic competition (WADA M1.2)
- Any concurrent EPO, HIF-PHI, blood doping, or other O2-economy modifier
References
Sihn et al. 2010 — Improvement of cardiac function in mice via ITPP-mediated rightward shift of the oxyhemoglobin dissociation curve (PMID 20736389)
foundational mouse cardiac stress + endurance paper
View StudyKieda et al. 2013 — ITPP relieves tumor hypoxia and inhibits tumor growth (J Mol Med)
oncology mechanism paper
View StudyApostolova et al. 2016 — Pharmacological characterization of ITPP
detailed allosteric mechanism + P50 shift quantification
View StudyFylaktakidou et al. 2005 — Inositol tripyrophosphates: a new family of allosteric effectors of hemoglobin
original synthesis and characterization (Lehn lab, Strasbourg)
View StudyWADA Prohibited List — M1.2 Artificial Enhancement of Oxygen Transfer/Delivery
regulatory status, banned in and out of competition
View StudyThevis et al. — Mass spectrometric detection of ITPP in doping control (Drug Test Anal)
WADA-relevant LC-MS/MS detection methodology
View StudyBiolley et al. — ITPP red blood cell loading and oxygen affinity (preclinical)
RBC loading kinetics
View StudyUSADA — Spirit of Sport: Blood Doping
athlete-relevant context for M1 prohibitions including ITPP
View StudyAprahamian / Strasbourg HCC Phase Ib trial of OXY111A (ClinicalTrials.gov NCT02528526)
only registered human ITPP trial of meaningful size
View StudyEMA Orphan Designations — OXY111A
investigational drug status; orphan designation for hepatocellular carcinoma
View StudyWikipedia — 2,3-Bisphosphoglyceric acid
natural allosteric effector that ITPP mimics
View StudyWikipedia — Hemoglobin and oxygen transport
Bohr effect, oxygen dissociation curve, allosteric regulation
View StudyPubMed search — ITPP myo-inositol trispyrophosphate
literature tracker
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.